A review of the antimicrobial activity of clavulanate

Open Access
Publisher Website
Google Scholar
Abstract
Clavulanate is a broad-spectrum β-lactamase inhibitor, with activity against many of the chromosomally and plasmid-mediated β-lactamases of both Gram-positive and Gram-negative bacteria. Although clavulanate has minimal antibacterial activity in vitro, accumulating evidence suggests that it may have an effect on pathogenic bacteria regardless of β-lactamase production. Like other β-lactams, clavulanate has been shown to bind to penicillin-binding proteins (PBPs) in Gram-positive and Gram-negative bacteria. It was found to bind selectively to PBP3 in Streptococcus pneumoniae. It has been suggested that complementary binding to different PBPs and subsequent effects on autolysis contribute to the enhancement of the activity of other β-lactams by clavulanate. In addition, co-amoxiclav has been shown to enhance the intracellular killing functions of human polymorphonuclear cells (PMNs) in studies undertaken with β-lactamase-producing and non-β-lactamase-producing strains of bacteria. These data from in vitro and cell culture systems have been reflected in vivo, where clavulanate enhanced the activity of amoxicillin against non-β-lactamase-producing organisms. Further studies are required to determine whether the effects seen within in vitro and in vivo animal studies have clinical significance.

This publication has 0 references indexed in Scilit: